LipoMedix Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $56K

  • Investors
  • 1

LipoMedix General Information

Description

Operator of a healthcare company intended to offer cancer therapy based on liposome delivery. The company's therapy involves developing anti-cancer drugs for different types of tumors, especially those derived from the gastrointestinal tract, including the stomach, pancreas, and colorectal, enabling patients to receive safer therapy with a potent anti-tumor effect.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Corporate Office
  • Sherman Administration Building
  • Derech Ruppin 1, Giv'at Ram
  • Jerusalem 9139001
  • Israel
+972
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Rafael Holdings
Corporate Office
  • Sherman Administration Building
  • Derech Ruppin 1, Giv'at Ram
  • Jerusalem 9139001
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LipoMedix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Grant 01-Jul-2019 $56K Completed Generating Revenue
5. Later Stage VC 01-Apr-2019 Completed Generating Revenue
4. Merger/Acquisition 24-Jun-2018 Completed Generating Revenue
3. Grant 01-May-2016 Completed Startup
2. Seed Round Completed Startup
1. Accelerator/Incubator Completed Startup
To view LipoMedix’s complete valuation and funding history, request access »

LipoMedix Patents

LipoMedix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2022517352-A Liposomal compositions and production methods containing liposomal prodrugs of mitomycin c Pending 11-Jan-2019
AU-2020207026-A1 Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture Inactive 11-Jan-2019
CA-3126211-A1 Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture Active 11-Jan-2019
EP-3908261-A1 Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture Pending 11-Jan-2019
US-12171746-B2 Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture Active 11-Jan-2019 A61K31/407
To view LipoMedix’s complete patent history, request access »

LipoMedix Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Innovation Authority Government
Integra Holdings Venture Capital Minority
Kepler Holdings Venture Capital Minority
Yissum Accelerator/Incubator
To view LipoMedix’s complete investors history, request access »

LipoMedix FAQs

  • When was LipoMedix founded?

    LipoMedix was founded in 2011.

  • Where is LipoMedix headquartered?

    LipoMedix is headquartered in Jerusalem, Israel.

  • What industry is LipoMedix in?

    LipoMedix’s primary industry is Drug Discovery.

  • Is LipoMedix a private or public company?

    LipoMedix is a Private company.

  • What is LipoMedix’s current revenue?

    The current revenue for LipoMedix is .

  • How much funding has LipoMedix raised over time?

    LipoMedix has raised $1.12M.

  • Who are LipoMedix’s investors?

    Innovation Authority, Integra Holdings, Kepler Holdings, and Yissum have invested in LipoMedix.

  • When was LipoMedix acquired?

    LipoMedix was acquired on 01-Jul-2019.

  • Who acquired LipoMedix?

    LipoMedix was acquired by Rafael Holdings.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process